获取途径

作者

Qingjun Li Xu Chang Jiaye Gu Yi Yang Jingzhong Ouyang Yanzhao Zhou Hong Zhao Jinxue Zhou

作者单位

⁵Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.Y., H.Z.) ³Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China (X.C.) ²These authors contributed equally to this work. ⁴School of Ophthalmology & Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China (J.G.) ¹Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China (Q.L., J.O., Y.Z., J.Z.)

刊名

Academic Radiology

年份

2025

ISSN

1076-6332

摘要

Rationale and Objectives The purpose of this study was to demonstrate the impact of postoperative adjuvant transarterial chemoembolization on the prognosis of patients with macrotrabecular-massive hepatocellular carcinoma . Materials and Methods This retrospective study used the clinical records of patients with resected MTM-HCC with/without adjuvant TACE at three centers between January 2015 and December 2022. The primary end point was recurrence free survival . The secondary end points were o...更多

Rationale and Objectives The purpose of this study was to demonstrate the impact of postoperative adjuvant transarterial chemoembolization on the prognosis of patients with macrotrabecular-massive hepatocellular carcinoma . Materials and Methods This retrospective study used the clinical records of patients with resected MTM-HCC with/without adjuvant TACE at three centers between January 2015 and December 2022. The primary end point was recurrence free survival . The secondary end points were overall survival and safety. Results A total of 559 eligible patients were classified into the adjuvant TACE group and the observation group. After propensity score matching analysis, both RFS and OS in the adjuvant TACE group were significantly better than the observation group. By Cox regression models, mALBI grade, types of hepatectomy, number, satellite lesion, without adjuvant TACE were identified as independent risk factors for RFS, and mALBI grade, number, maximum tumor size, satellite lesion, microvascular invasion, high AFP level, without adjuvant TACE were identified as independent risk factors for OS. The incidence of surgery-related adverse events had no significant difference between the two groups . The majority of AEs associated with adjuvant TACE were grade I , and no treatment-related deaths occurred in either group. Conclusions Adjuvant TACE significantly improved the RFS and OS of patients with resected MTM-HCC with acceptable toxicity.收起

文献类型

期刊

浏览量

3